Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
82.47
+0.08 (0.10%)
Sep 1, 2026, 12:27 PM EDT - Market open
Arrowhead Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Revenue Revenue Growth | 669.5 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 |
Revenue Growth | 16.84% | 23258.15% | -98.52% | -1.03% | 75.89% | 57.16% |
Gross Profit Gross Profit Growth | 669.5 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 |
Operating Income Operating Income Growth | -226.44 | 98.35 | -601.08 | -205 | -178.51 | -149.04 |
Net Income Net Income Growth | -319.96 | -1.63 | -599.49 | -205.28 | -176.06 | -140.85 |
Earnings Per Share EPS Growth | -2.28 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
GSK GSK Growth | - | 2.65 | 2.69 | 29.66 | 124.76 | - |
Takeda Takeda Growth | - | - | 0.87 | 162.52 | 85.83 | 90.78 |
Sarepta Sarepta Growth | 424.07 | 696.8 | - | - | - | - |
Sanofi Sanofi Growth | 141.98 | 130 | - | - | - | - |
Revenue (Total) Revenue (Total) Growth | 669.5 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Investments Cash & Investments Growth | 1,598 | 917.47 | 677.46 | 395.73 | 369.1 | 367.79 |
Total Debt Total Debt Growth | 1,379 | 743.98 | 851.91 | 383.5 | 81.58 | 25.55 |
Net Cash (Debt) Net Cash Growth | 218.46 | 173.49 | -174.45 | 12.23 | 287.52 | 342.24 |
Net Cash Growth | 22.88% | - | - | -95.75% | -15.99% | 16.27% |
Net Cash Per Share Net Cash Per Share Growth | 1.56 | 1.30 | -1.46 | 0.11 | 2.73 | 3.30 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -59.06 | 179.55 | -462.85 | -153.89 | -136.13 | 171.31 |
Capital Expenditures CapEx Growth | -16.06 | -22.67 | -141.47 | -176.74 | -52.78 | -23.57 |
Free Cash Flow Free Cash Flow Growth | -75.11 | 156.89 | -604.32 | -330.63 | -188.91 | 147.75 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -33.82% | 11.86% | -16927.06% | -85.16% | -73.39% | -107.77% |
Pretax Margin | -37.65% | 6.21% | -17247.54% | -85.78% | -71.01% | -101.85% |
Profit Margin | -47.79% | -0.20% | -16882.37% | -85.27% | -72.39% | -101.85% |
FCF Margin | -11.22% | 18.92% | -17018.31% | -137.34% | -77.67% | 106.84% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 1, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Forward PE | - | 140.94 | 140.94 | 140.94 | 140.94 | 140.94 |
P/FCF Ratio | - | 30.40 | - | - | - | 44.06 |
PS Ratio | 17.38 | 5.75 | 678.12 | 11.96 | 14.38 | 47.07 |